Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Benjamin L. Ebert, M.D., D.Phil.

Co-Author

This page shows the publications co-authored by Benjamin Ebert and Emma Fink.
Connection Strength

2.292
  1. CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice. Blood. 2018 10 04; 132(14):1535-1544.
    View in: PubMed
    Score: 0.813
  2. The novel mechanism of lenalidomide activity. Blood. 2015 Nov 19; 126(21):2366-9.
    View in: PubMed
    Score: 0.669
  3. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature. 2020 09; 585(7824):293-297.
    View in: PubMed
    Score: 0.231
  4. Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs. Blood. 2019 07 11; 134(2):160-170.
    View in: PubMed
    Score: 0.214
  5. Lenalidomide induces ubiquitination and degradation of CK1a in del(5q) MDS. Nature. 2015 Jul 09; 523(7559):183-188.
    View in: PubMed
    Score: 0.164
  6. Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia. J Exp Med. 2014 Apr 07; 211(4):605-12.
    View in: PubMed
    Score: 0.150
  7. Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome. Elife. 2018 08 01; 7.
    View in: PubMed
    Score: 0.051
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.